AVTX Earnings & Financial Statements
Avalo Therapeutics, Inc.
$12.01
-$1.23(-9.29%)
32
Overall
60
Value
9
Tech
28
Quality
Market Cap
$644.10M
Volume
1.65M
52W Range
$12.51 - $24.27
Target Price
$44.08
AVTX earnings and financial statements: Avalo Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AVTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $59.0K | $441.0K | $1.92M | $18.05M | $5.40M |
| Cost of revenue | - | $366.0K | $1.28M | $3.43M | $1.49M |
| Operating income | -$72.92M | -$68.51M | -$27.35M | -$37.44M | -$82.13M |
| EBITDA | -$82.10M | -$38.16M | -$27.95M | -$35.91M | -$80.50M |
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -$84.38M |
| EPS (diluted) | $-5.84 | $-20.91 | $-114.00 | $-1063.20 | $-14342.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $116.46M | $150.73M | $20.99M | $33.37M | $80.21M |
| Total liabilities | $33.41M | $17.70M | $13.69M | $44.28M | $57.13M |
| Shareholders’ equity | $83.05M | $133.03M | $7.30M | -$10.91M | $23.08M |
| Cash and equivalents | $15.86M | $134.55M | $7.42M | $13.17M | $54.59M |
| Long-term debt | - | - | - | $13.49M | $32.83M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$51.50M | -$49.06M | -$30.68M | -$26.75M | -$70.89M |
| Capital expenditure | - | - | -$133.0K | -$95.0K | -$113.0K |
| Free cash flow | -$51.50M | -$49.06M | -$30.68M | -$26.85M | -$71.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVTX | $12.01 | -9.3% | 1.65M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Avalo Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW